Terms: = Lymphoma AND ABCG2, ABC15, ABCP, BCRP, BCRP1, BMDP, CD338, CDw338, EST157481, GOUT1, MRX, MXR, MXR-1, MXR1, UAQTL1 AND Treatment
72 results:
1. Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach.
Hanley MJ; Yeo KR; Tugnait M; Iwasaki S; Narasimhan N; Zhang P; Venkatakrishnan K; Gupta N
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):624-637. PubMed ID: 38288787
[TBL] [Abstract] [Full Text] [Related]
2. Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.
Kelvin JM; Chimenti ML; Zhang DY; Williams EK; Moore SG; Humber GM; Baxter TA; Birnbaum LA; Qui M; Zecca H; Thapa A; Jain J; Jui NT; Wang X; Fu H; Du Y; Kemp ML; Lam WA; Graham DK; DeRyckere D; Dreaden EC
J Control Release; 2023 Sep; 361():470-482. PubMed ID: 37543290
[TBL] [Abstract] [Full Text] [Related]
3. Effects of splicing-regulatory polymorphisms in ABCC2, abcg2, and ABCB1 on methotrexate exposure in Chinese children with acute lymphoblastic leukemia.
Li M; Kong XY; Wang SM
Cancer Chemother Pharmacol; 2023 Jan; 91(1):77-87. PubMed ID: 36463535
[TBL] [Abstract] [Full Text] [Related]
4. Seleno-vs. thioether triazine derivatives in search for new anticancer agents overcoming multidrug resistance in lymphoma.
Ali W; Garbo S; Kincses A; Nové M; Spengler G; Di Bello E; Honkisz-Orzechowska E; Karcz T; Szymańska E; Żesławska E; Starek M; Dąbrowska M; Nitek W; Kucwaj-Brysz K; Pyka P; Fioravanti R; Jacob C; Battistelli C; Zwergel C; Handzlik J
Eur J Med Chem; 2022 Dec; 243():114761. PubMed ID: 36179403
[TBL] [Abstract] [Full Text] [Related]
5. Pharmacogenetics of induction therapy-related toxicities in childhood acute lymphoblastic leukemia patients treated with UKALL 2003 protocol.
Aslam S; Ameer S; Shabana NA; Ahmed M
Sci Rep; 2021 Dec; 11(1):23757. PubMed ID: 34887513
[TBL] [Abstract] [Full Text] [Related]
6. Multiplex Single-Cell Analysis of Cancer Cells Enables Unbiased Uncovering Subsets Associated with Cancer Relapse: Heterogeneity of Multidrug Resistance in Precursor B-ALL.
Zhou Y; Wai-Choi Tse E; Leung R; Cheung E; Li H; Sun H
ChemMedChem; 2022 Feb; 17(3):e202100638. PubMed ID: 34783169
[TBL] [Abstract] [Full Text] [Related]
7. Genetic factors in treatment-related cardiovascular complications in survivors of childhood acute lymphoblastic leukemia.
Petrykey K; Rezgui AM; Guern ML; Beaulieu P; St-Onge P; Drouin S; Bertout L; Wang F; Baedke JL; Yasui Y; Hudson MM; Raboisson MJ; Laverdière C; Sinnett D; Andelfinger GU; Krajinovic M
Pharmacogenomics; 2021 Sep; 22(14):885-901. PubMed ID: 34505544
[No Abstract] [Full Text] [Related]
8. sATP‑binding cassette subfamily G member 2 enhances the multidrug resistance properties of human nasal natural killer/T cell lymphoma side population cells.
Wu S; Zhang X; Dong M; Yang Z; Zhang M; Chen Q
Oncol Rep; 2020 Oct; 44(4):1467-1478. PubMed ID: 32945520
[TBL] [Abstract] [Full Text] [Related]
9. Extrahepatic metabolism of ibrutinib.
Rood JJM; Jamalpoor A; van Hoppe S; van Haren MJ; Wasmann RE; Janssen MJ; Schinkel AH; Masereeuw R; Beijnen JH; Sparidans RW
Invest New Drugs; 2021 Feb; 39(1):1-14. PubMed ID: 32623551
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Zappulo E; Scotto R; Buonomo AR; Maraolo AE; Pinchera B; Gentile I
Expert Opin Pharmacother; 2020 Feb; 21(3):261-273. PubMed ID: 31914336
[No Abstract] [Full Text] [Related]
11. Interactions of Alectinib with Human ATP-Binding Cassette Drug Efflux Transporters and Cytochrome P450 Biotransformation Enzymes: Effect on Pharmacokinetic Multidrug Resistance.
Hofman J; Sorf A; Vagiannis D; Sucha S; Novotna E; Kammerer S; Küpper JH; Ceckova M; Staud F
Drug Metab Dispos; 2019 Jul; 47(7):699-709. PubMed ID: 31068367
[TBL] [Abstract] [Full Text] [Related]
12. Methotrexate Disposition in Pediatric Patients with Acute Lymphoblastic Leukemia: What Have We Learnt From the Genetic Variants of Drug Transporters.
Hu YH; Zhou L; Wang SS; Jing X; Guo HL; Sun F; Zhang Y; Chen F; Xu J; Ji X
Curr Pharm Des; 2019; 25(6):627-634. PubMed ID: 30931851
[TBL] [Abstract] [Full Text] [Related]
13. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
Reck M; Mok TSK; Nishio M; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Lee A; Coleman S; Deng Y; Kowanetz M; Shankar G; Lin W; Socinski MA;
Lancet Respir Med; 2019 May; 7(5):387-401. PubMed ID: 30922878
[TBL] [Abstract] [Full Text] [Related]
14. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines.
Orellana-Serradell O; Herrera D; Castellón EA; Contreras HR
Asian J Androl; 2019; 21(5):460-467. PubMed ID: 30880686
[TBL] [Abstract] [Full Text] [Related]
15. Ex vivo resistance in childhood acute lymphoblastic leukemia: Correlations between bcrp, MRP1, MRP4 and MRP5 ABC transporter expression and intracellular methotrexate polyglutamate accumulation.
Jaramillo AC; Cloos J; Lemos C; Stam RW; Kaspers GJL; Jansen G; Peters GJ
Leuk Res; 2019 Apr; 79():45-51. PubMed ID: 30849662
[TBL] [Abstract] [Full Text] [Related]
16. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity.
Lee-Sherick AB; Jacobsen KM; Henry CJ; Huey MG; Parker RE; Page LS; Hill AA; Wang X; Frye SV; Earp HS; Jordan CT; DeRyckere D; Graham DK
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385715
[TBL] [Abstract] [Full Text] [Related]
17. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
[TBL] [Abstract] [Full Text] [Related]
18. Atezolizumab for First-Line treatment of Metastatic Nonsquamous NSCLC.
Socinski MA; Jotte RM; Cappuzzo F; Orlandi F; Stroyakovskiy D; Nogami N; Rodríguez-Abreu D; Moro-Sibilot D; Thomas CA; Barlesi F; Finley G; Kelsch C; Lee A; Coleman S; Deng Y; Shen Y; Kowanetz M; Lopez-Chavez A; Sandler A; Reck M;
N Engl J Med; 2018 Jun; 378(24):2288-2301. PubMed ID: 29863955
[TBL] [Abstract] [Full Text] [Related]
19. P-glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450-3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Wagenaar E; Beijnen JH; Schinkel AH
Int J Cancer; 2018 Oct; 143(8):2029-2038. PubMed ID: 29744867
[TBL] [Abstract] [Full Text] [Related]
20. APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency.
Tsai CY; Sun S; Zhang H; Local A; Su Y; Gross LA; Rice WG; Howell SB
Mol Cancer Ther; 2018 Jun; 17(6):1167-1176. PubMed ID: 29626126
[TBL] [Abstract] [Full Text] [Related]
[Next]
